XML 13 R2.htm IDEA: XBRL DOCUMENT v3.24.2
Consolidated Balance Sheets - USD ($)
$ in Millions
Jun. 30, 2024
Dec. 31, 2023
Current assets:    
Cash and cash equivalents $ 2,258 $ 3,226
Accounts receivables, net of allowance for credit losses of $95 million as of June 30, 2024 and as of December 31, 2023. 3,766 3,408
Inventories 3,927 4,021
Prepaid expenses 1,096 1,255
Other current assets 517 504
Assets held for sale 69 70
Total current assets 11,632 12,485
Deferred income taxes 2,000 1,812
Other non-current assets 434 470
Property, plant and equipment, net 5,573 5,750
Operating lease right-of-use assets, net 358 397
Identifiable intangible assets, net 4,853 5,387
Goodwill 16,488 [1] 17,177
Total assets 41,338 43,479
Current liabilities:    
Short-term debt 2,094 1,672
Sales reserves and allowances 3,700 3,535
Accounts payables 2,366 2,602
Employee-related obligations 492 611
Accrued expenses 2,840 2,771
Other current liabilities 1,191 1,044
Liabilities held for sale 356 13
Total current liabilities 13,037 12,247
Long-term liabilities:    
Deferred income taxes 553 606
Other taxes and long-term liabilities 4,356 4,019
Senior notes and loans 16,547 18,161
Operating lease liabilities 281 320
Total long-term liabilities 21,737 23,106
Commitments and contingencies, see note 10
Total liabilities 34,774 35,353
Teva shareholders' equity:    
Ordinary shares of NIS 0.10 par value per share; June 30, 2024 and December 31, 2023: authorized 2,495 million shares; issued 1,239 million shares and 1,227 million shares, respectively. 58 57
Additional paid-in capital 27,829 27,807
Accumulated deficit (14,519) (13,534)
Accumulated other comprehensive loss (2,881) (2,697)
Treasury shares as of June 30, 2024 and December 31, 2023: 106 million ordinary shares (4,128) (4,128)
Stockholders' equity attributable to Teva shareholders 6,359 7,506
Non-controlling interests 204 620
Total equity 6,563 8,126
Total liabilities and equity $ 41,338 $ 43,479
[1] Cumulative goodwill impairment as of June 30, 2024 and December 31, 2023 was approximately $28.7 billion and $28.3 billion, respectively.